Maternal, newborn and breast milk concentrations of elexacaftor/tezacaftor/ivacaftor in a F508del heterozygous woman with cystic fibrosis following successful pregnancy

Maternal, newborn and breast milk concentrations of elexacaftor/tezacaftor/ivacaftor in a F508del heterozygous woman with cystic fibrosis following successful pregnancy

With the introduction of elexacaftor/tezacaftor/ivacaftor (ETI), more women with cystic fibrosis (CF) are likely to grow families. Hence, an understanding long-term safety and effects of CFTR modulators on fertile women and children while monitoring their concentrations is crucial. Here, we report o...

Full description

Bibliographic Details
Main Authors: Pietro Ripani, Matteo Mucci, Stefano Pantano, Maria Di Sabatino, Francesca Collini, Giulia Ferri, Mario Romano, Antonio Recchiuti
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-12-01
Series:Frontiers in Medicine
Subjects:
novel therapies
pregnancy
drug monitoring
F508del CFTR
CFTR modulator therapy
R334W CFTR
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2023.1274303/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2023.1274303/full

Similar Items